Provention Bio secures FDA approval for TZIELD to delay diabetes
TZIELD is an anti-CD3-directed antibody, indicated for administration as a once-daily intravenous infusion for 14 days, to delay…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Nov 22
TZIELD is an anti-CD3-directed antibody, indicated for administration as a once-daily intravenous infusion for 14 days, to delay…
14 Nov 22
The FDA approval is supported by positive results from the Phase 3 POSEIDON study, which showed a significant…
11 Nov 22
VidPrevtyn Beta is a monovalent, recombinant-protein, next-generation Covid-19 vaccine developed by Sanofi, leveraging GSK’s pandemic adjuvant, and is…
10 Nov 22
The British health regulator has expanded the conditional marketing authorisation (CMA) for Novavax’s Nuvaxovid as a booster dose…
04 Nov 22
The Breakthrough Therapy Designation was granted based on updated data from the Phase 2 MagnetisMM-3 study, in which…
03 Nov 22
The current FDA approval expands Vemlidy’s previous indication as a once-daily therapy to treat chronic HBV infection in…
31 Oct 22
Actemra is indicated for the treatment of hospitalised Covid-19 patients who are on systemic corticosteroids, and require supplemental…
27 Oct 22
Capivasertib plus Faslodex showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to placebo…
26 Oct 22
Tecvayli is an off-the-shelf, subcutaneous therapy, indicated for subcutaneous administration for the treatment of relapsed or refractory multiple…
17 Oct 22
Boehringer Ingelheim is seeking approval in the European Union for its IL-36R inhibitor in generalised pustular psoriasis based…